BioPorto Diagnostics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
117 4th Ave Ste 202, Needham, Massachuse...Phone Number
(844) 424-6767Website
www.bioporto.usRevenue
$7.5 MillionIndustry
About BioPorto Diagnostics
BioPorto Diagnostics Inc. specializes in innovative solutions for healthcare, specifically focusing on acute kidney injury (AKI) risk assessment through its product ProNephro AKI (NGAL). This product is the first FDA-cleared test for assessing pediatric AKI risk, highlighting the company's commitment to improving patient outcomes. The intended clients include healthcare systems, clinical teams, patients, caregivers, and laboratories. BioPorto aims to revolutionize pediatric kidney care with its range of NGAL products and is set for commercial availability through Roche Diagnostics in 2025.Explore more
BioPorto Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to BioPorto Diagnostics
Compare insights from companies similar to BioPorto Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
BioPorto Diagnostics Tech Stack
A closer look at the technologies used by BioPorto Diagnostics
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioPorto Diagnostics
Sign Up For FreeTo access detailed company insights
BioPorto Diagnostics Inc. specializes in innovative solutions for healthcare, specifically focusing on acute kidney injury (AKI) risk assessment through its product ProNephro AKI (NGAL). This product is the first FDA-cleared test for assessing pediatric AKI risk, highlighting the company's commitment to improving patient outcomes. The intended clie... Read More
